(45) applied a remission definition of “HbA1c < 7.0% without glucose-lowering medications.” In patients with new-onset diabetes, those receiving 12 weeks of exenatide following a 3-week intensive insulin pump regimen had significantly higher cumulative remission rates at one and two years (68.2% and 53.0%, respectively) compared to those in the insulin-only group (36.5% and 31.8%, respectively). This evidence concerns the gene INS and diabetes mellitus.